Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Editas Medicine's total debt was $56.82M at Sep 30, 2026. For fiscal 2025 it was $58.61M, up 2.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.61M | +2.0% |
| FY2024 | Dec 31, 2024 | $57.43M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $56.82M | -3.8% |
| Q2 FY2026 | Jun 30, 2026 | $55.74M | -1.6% |
| Q1 FY2026 | Mar 31, 2026 | $54.68M | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | $58.61M | +2.0% |
| Q3 FY2025 | Sep 30, 2025 | $59.07M | – |
| Q2 FY2025 | Jun 30, 2025 | $56.67M | – |
| Q1 FY2025 | Mar 31, 2025 | $54.58M | – |
| Q4 FY2024 | Dec 31, 2024 | $57.43M | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
See a number that looks wrong?